NRx Pharma Q2 FY26 net loss narrows to $16.52 million; revenue rises to $1.1 million - NRXP News | RalliesNRx Pharma Q2 FY26 net loss narrows to $16.52 million; revenue rises to $1.1 million
N
NRXP• Quarterly results improve modestly
- NRX Pharmaceuticals posted a GAAP net loss of $16.52 million for the quarter ended June 30, 2026, narrowing from $17.58 million.
- Revenue was $1.1 million, versus no revenue a year earlier, reflecting patient services from Dura acquired in September 2025.
Cash balance increases after offering
- Cash rose to $26.69 million at June 30, 2026 from $7.8 million at December 31, 2025, following $20.7 million in net offering proceeds.
Operating loss widens as expenses increase
- Operating loss widened to $6.51 million from $3.73 million as total operating expense climbed to $7.61 million from $3.73 million.
- Other expense fell to from as losses tied to convertible notes and note conversions dropped to none.
$10.02 million
$13.85 million
•
